U-M developed diabetes treatment technology being evaluated in Europe

New diabetes treatment technology developed at the University of Michigan Health System that helps patients better manage their therapy regimen is being evaluated in Europe and has the potential become part of standard care for insulin users.

About a quarter of diabetes patients are treated with insulin injection — a treatment option that ideally should be adjusted weekly by health care professionals. However, as nearly 26 million Americans have diabetes and another 70 million have pre-diabetes, the health care system is ill-equipped to meet this requirement, leaving many patients unable to maintain healthy blood sugar ranges.

Created by Israel Hodish, M.D., professor of internal medicine at U-M, the d-Nav™ Diabetes Insulin Guidance System has the potential to fill the gap when diabetes patients are unable to adjust their treatment with their health care team, by automating insulin dosage adjustments based on a patient’s blood glucose pattern.

Once set up, the technology requires no health care provider oversight or input, making it viable for a large number of patients.

d-Nav is currently being evaluated in Northern Ireland and an observational study will begin at the Heartlands Diabetes Centre in Birmingham, England early this year.

“The d-Nav Diabetes Insulin Guidance System is an excellent example of translational research at the University Medical School leading to products that can dramatically improve global health care,” says Hodish, who co-founded Ann Arbor-based Hygieia to further develop and commercialize the technology. “This new technology automates the therapy adjustment process, making it feasible for millions of insulin users to receive continuity of consistent care.”

This entry was posted in Clinical & Translational Research, UMHS in the News. Bookmark the permalink.